A citation-based method for searching scientific literature


List of co-cited articles
483 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Systematic overview of warfarin and its drug and food interactions.
Anne M Holbrook, Jennifer A Pereira, Renee Labiris, Heather McDonald, James D Douketis, Mark Crowther, Philip S Wells. Arch Intern Med 2005
718
16

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
Julia Kirchheiner, Elke Störmer, Christian Meisel, Nadine Steinbach, Ivar Roots, Jürgen Brockmöller. Pharmacogenetics 2003
82
12

Interactions of warfarin with drugs and food.
P S Wells, A M Holbrook, N R Crowther, J Hirsh. Ann Intern Med 1994
412
12


Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.
Francesco Dentali, James D Douketis, Karen Woods, Lehana Thabane, Gary Foster, Anne Holbrook, Mark Crowther. Ann Pharmacother 2006
14
28

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
F Catella-Lawson, M P Reilly, S C Kapoor, A J Cucchiara, S DeMarco, B Tournier, S N Vyas, G A FitzGerald. N Engl J Med 2001
996
12

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Marisa Battistella, Muhammad M Mamdami, David N Juurlink, Linda Rabeneck, Andreas Laupacis. Arch Intern Med 2005
109
12

Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Tsukasa Uno, Mikiko Shimizu, Norio Yasui-Furukori, Kazunobu Sugawara, Tomonori Tateishi. Br J Clin Pharmacol 2006
27
14

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
J I Schwartz, K J Bugianesi, D L Ebel, M De Smet, R Haesen, P J Larson, A Ko, R Verbesselt, T L Hunt, R Lins,[...]. Clin Pharmacol Ther 2000
44
12

Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.
A Karim, D Tolbert, A Piergies, R C Hubbard, K Harper, C B Wallemark, M Slater, G S Geis. J Clin Pharmacol 2000
25
16


Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
B A Hamelin, A Bouayad, J Méthot, J Jobin, P Desgagnés, P Poirier, J Allaire, J Dumesnil, J Turgeon. Clin Pharmacol Ther 2000
108
12

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Thibaud Damy, Françoise Pousset, Henri Caplain, Jean-Sébastien Hulot, Philippe Lechat. Fundam Clin Pharmacol 2004
54
12

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
D Dai, D C Zeldin, J A Blaisdell, B Chanas, S J Coulter, B I Ghanayem, J A Goldstein. Pharmacogenetics 2001
386
9

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Ulrich M Zanger, Sebastian Raimundo, Michel Eichelbaum. Naunyn Schmiedebergs Arch Pharmacol 2004
595
9

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.
Munir Pirmohamed, Sally James, Shaun Meakin, Chris Green, Andrew K Scott, Thomas J Walley, Keith Farrar, B Kevin Park, Alasdair M Breckenridge. BMJ 2004
9

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
Elena García-Martín, Carmen Martínez, Beatriz Tabarés, Jesús Frías, José A G Agúndez. Clin Pharmacol Ther 2004
139
9

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Scott D Solomon, John J V McMurray, Marc A Pfeffer, Janet Wittes, Robert Fowler, Peter Finn, William F Anderson, Ann Zauber, Ernest Hawk, Monica Bertagnolli. N Engl J Med 2005
9

The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption.
D W Kaufman, J P Kelly, B E Wiholm, A Laszlo, J E Sheehan, R S Koff, S Shapiro. Am J Gastroenterol 1999
75
9

Bleeding complications in patients on celecoxib and warfarin.
L Chung, E F Chakravarty, P Kearns, C Wang, T M Bush. J Clin Pharm Ther 2005
17
17




Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.
Susanne Oksbjerg Dalton, Christoffer Johansen, Lene Mellemkjaer, Bente Nørgård, Henrik Toft Sørensen, Jørgen H Olsen. Arch Intern Med 2003
269
9

Assessment of potential drug-drug interactions with a prescription claims database.
Daniel C Malone, David S Hutchins, Heather Haupert, Philip Hansten, Babette Duncan, Robin C Van Bergen, Steve L Solomon, Richard B Lipton. Am J Health Syst Pharm 2005
86
9

Concomitant coumarin-NSAID therapy and risk for bleeding.
Ellen A J Knijff-Dutmer, Gelte A Schut, Martin A F J van de Laar. Ann Pharmacother 2003
47
9

Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.
K Kosuge, Y Jun, H Watanabe, M Kimura, M Nishimoto, T Ishizaki, K Ohashi. Drug Metab Dispos 2001
30
10

A taste of Chinese medicine!
M B Izzat, A P Yim, M H El-Zufari. Ann Thorac Surg 1998
75
9

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Norio Yasui-Furukori, Masato Saito, Tsukasa Uno, Takenori Takahata, Kazunobu Sugawara, Tomonori Tateishi. J Clin Pharmacol 2004
44
9

Chinese herbs and warfarin potentiation by 'danshen'.
C M Yu, J C Chan, J E Sanderson. J Intern Med 1997
95
9

Herb-drug interactions: review and assessment of report reliability.
A Fugh-Berman, E Ernst. Br J Clin Pharmacol 2001
214
9

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Craig R Lee, Joyce A Goldstein, John A Pieper. Pharmacogenetics 2002
509
9

Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Alberto Pilotto, Davide Seripa, Marilisa Franceschi, Carlo Scarcelli, Donatella Colaizzo, Elvira Grandone, Valeria Niro, Angelo Andriulli, Gioacchino Leandro, Francesco Di Mario,[...]. Gastroenterology 2007
117
9


Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
791
9

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Loes E Visser, Ron H N van Schaik, Martin van Vliet, Paul H Trienekens, Peter A G M De Smet, Arnold G Vulto, Albert Hofman, Cornelia M van Duijn, Bruno H Ch Stricker. Thromb Haemost 2004
79
9

Clinical consequences of cytochrome P450 2C9 polymorphisms.
Julia Kirchheiner, Jürgen Brockmöller. Clin Pharmacol Ther 2005
340
9

Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors.
J A Stading, M Z Skrabal, M A Faulkner. Am J Health Syst Pharm 2001
16
18

Potential interaction between celecoxib and warfarin.
K K Haase, C H Rojas-Fernandez, L Lane, D A Frank. Ann Pharmacother 2000
26
11

Warfarin and celecoxib interaction.
T L Mersfelder, L R Stewart. Ann Pharmacother 2000
37
9

Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
Karen N van Dijk, Arian W Plat, Alieke A C van Dijk, Margriet Piersma-Wichers, Anne M B de Vries-Bots, Jennita Slomp, Lolkje T W de Jong-van den Berg, Jacobus R B J Brouwers. Thromb Haemost 2004
30
10


Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
A E Rettie, L C Wienkers, F J Gonzalez, W F Trager, K R Korzekwa. Pharmacogenetics 1994
418
9

The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery.
Maarten J Beinema, Petra H de Jong, Har J M Salden, Merel van Wijnen, Jan van der Meer, Jacobus R B J Brouwers. Mol Diagn Ther 2007
11
27

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Hui-Yan Shi, Jin Yan, Wen-Hui Zhu, Guo-Ping Yang, Zhi-Rong Tan, Wei-Hua Wu, Gan Zhou, Xiao-Ping Chen, Dong-Sheng Ouyang. Eur J Clin Pharmacol 2010
39
9

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, Byung-Hwan Yang, Sang-Goo Shin, Dong-Seok Yim. Br J Clin Pharmacol 2002
36
9

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
William H Geerts, David Bergqvist, Graham F Pineo, John A Heit, Charles M Samama, Michael R Lassen, Clifford W Colwell. Chest 2008
9

Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
K T Olkkola, A V Brunetto, M J Mattila. Clin Pharmacokinet 1994
66
9

Clinical pharmacokinetics of naproxen.
N M Davies, K E Anderson. Clin Pharmacokinet 1997
89
9

Dabigatran versus warfarin in patients with atrial fibrillation.
Stuart J Connolly, Michael D Ezekowitz, Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul A Reilly, Ellison Themeles, Jeanne Varrone,[...]. N Engl J Med 2009
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.